Tricin Inhibits Human Osteosarcoma Cell Metastasis via Suppression of ZNF503 and the PI3K–PIP3–Akt Pathway
Drug Development Research · 2026
DOI: 10.1002/ddr.70374 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Development Research, 2026. Verfasst von Chia-Hsuan Chou und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Research, Chung Shan Medical University Hospital, Taichung, Taiwan. Hauptthemen laut MEDLINE: Osteosarcoma, Bone Neoplasms, Flavonoids. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Osteosarcoma is the most common primary malignant bone tumor and is associated with a high mortality rate due to its pronounced metastatic potential. Although tricin has been proposed as a chemosensitizer in various malignancies, its anti‐metastatic effect in osteosarcoma remains poorly characterized. This study investigated whether tricin suppresses metastasis in human osteosarcoma cells and explored the underlying molecular mechanisms. Our results revealed that tricin significantly inhibited the migration and invasion of U2OS and Saos‐2 osteosarcoma cells and downregulated ZNF503 expression at both the mRNA and protein levels. Similarly, siRNA‐mediated knockdown of ZNF503 suppressed cell migration, as confirmed by immunofluorescence analysis. Tricin treatment also reduced phosphorylation of PI3K and Akt, without affecting the activation of ERK1/2, JNK1/2, or p38. Additionally, intracellular levels of PIP3 were diminished following tricin exposure. Notably, the Akt activator SC‐79 significantly reversed tricin‐induced suppression of both ZNF503 expression and cell migration in U2OS and Saos‐2 cells. In conclusion, these findings suggest that ZNF503 inhibits osteosarcoma cell motility via the PI3K–PIP3–Akt signaling axis and that tricin exerts anti‐metastatic effects by targeting this pathway. Tricin may therefore represent a promising therapeutic agent for inhibiting osteosarcoma metastasis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Research, Chung Shan Medical University Hospital, Taichung, Taiwan.
- Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan.
- Department of Pharmacology, School of Medicine, China Medical University, Taichung, Taiwan.
- Department of Medical Laboratory Science and Biotechnology, Asia University, Taichung, Taiwan.
- Chinese Medicine Research Center, China Medical University, Taichung, Taiwan.
- Department of Orthopedics, Chung Shan Medical University Hospital, Taichung, Taiwan.
ORCID-Profile: Pei-Ni Chen, Yi-Hsien Hsieh, Chih-Hsin Tang, Shun-Fa Yang
Zitieren
APA
Chou, C. H., Yang, J. S., Chen, P. N., Hsieh, Y. H., Tang, C. H., Lin, Y. C., Yang, S. F., & Lu, K. H. (2026). Tricin Inhibits Human Osteosarcoma Cell Metastasis via Suppression of ZNF503 and the PI3K–PIP3–Akt Pathway. Drug Development Research. https://doi.org/10.1002/ddr.70374
Vancouver
Chou CH, Yang JS, Chen PN, Hsieh YH, Tang CH, Lin YC, et al. Tricin Inhibits Human Osteosarcoma Cell Metastasis via Suppression of ZNF503 and the PI3K–PIP3–Akt Pathway. Drug Development Research. 2026. doi:10.1002/ddr.70374
BibTeX
@article{Chou2026,
author = {Chou, Chia-Hsuan and Yang, Jia-Sin and Chen, Pei-Ni and Hsieh, Yi-Hsien and Tang, Chih-Hsin and Lin, Ya-Chiu and Yang, Shun-Fa and Lu, Ko-Hsiu},
title = {Tricin Inhibits Human Osteosarcoma Cell Metastasis via Suppression of ZNF503 and the PI3K–PIP3–Akt Pathway},
journal = {Drug Development Research},
year = {2026},
doi = {10.1002/ddr.70374}
}
EUVIMED